Is Compass Therapeutics (NASDAQ:CMPX) Gaining Momentum with Institutional Backing
Highlights,Compass Therapeutics sees increased institutional engagement, with major firms expanding their holdings.,Research firms adjust ratings, reflecting varied perspectives on the company’s market trajectory.,The company advances lead therapeutic can...
Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary ...
Compass Therapeutics' lead candidate, tovecimig, shows mixed data in various trials, with a significant upcoming phase 3 ...
Compass Therapeutics currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the sector are Castle Biosciences CSTL, BioMarin Pharmaceutical BMRN and Alnylam Pharmaceuticals ALNY.
As of December 31, 2024, cash and marketable securities were $127 million as compared to $152 million as of December 31, 2023, providing the ...
Overview: Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company in the U.S. focused on developing antibody-based therapeutics for oncology, with a market cap of $429.28 million.
Shares of Compass Therapeutics (NASDAQ:CMPX) were up 8% in afternoon trading Monday after Guggenheim initiated coverage of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback